Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

Can You Join FFI Research Without Learning Your PRNP Status?

At a Glance

Some fatal familial insomnia research studies let at-risk family members participate without learning whether they carry the family’s PRNP variant, but this is study-specific. Ask about blinding, privacy, future sample use, and genetic counseling before consenting.

Yes, it is sometimes possible to participate in fatal familial insomnia (FFI) and prion disease research without learning whether you carry a genetic variant. However, this depends entirely on the design of the specific study.

Some research initiatives, including specialized registries and certain proposed presymptomatic prevention trials, are designed to allow at-risk family members to participate while keeping their genetic status hidden from them (a “genotype-blinded” or “nondisclosure” approach) [1][2]. Because not every trial can accommodate this preference, you must carefully discuss your desire not to know your status with the research team before enrolling [3][4].

Important Note: Participating in research is completely voluntary and is different from receiving clinical care. An experimental study may offer no guaranteed personal benefit, and participating or declining will not affect your regular medical care. Research genetic testing is also different from clinical testing, and any research findings typically require a separate, clinically validated test before they are used to make medical decisions.

How Genotype-Blinded Studies Work

In a genotype-blinded study, researchers may test your DNA to determine if you carry the specific pathogenic PRNP variant identified in your family, but they will not reveal the results to you. It is important to note that not all PRNP variants cause FFI, so the study will look specifically for your family’s variant.

As an example of how this can work, a proposed prevention trial design for FFI explored allowing individuals who did not want to know their status to participate. In that proposed design, genetic carriers would receive an experimental treatment while non-carriers would receive a placebo, and the clinical examiners evaluating the participants’ health would remain blinded to their genetic status [1][2]. Other studies may use different designs, such as testing only carriers or using non-carriers as controls, which affects how blinding is maintained.

In observational research or registries, researchers might follow both mutation carriers and non-carriers over time. They gather baseline data through repeated clinical visits, brain MRI, spinal fluid collection, and sleep studies, without returning individual genetic results to the participants [5][3]. Keep in mind that study procedures like lumbar punctures or MRIs carry their own physical burdens and risks, which should be detailed in the study’s informed consent document. You always have the right to ask about the risks of individual procedures and whether they are optional.

Discussing Your Preference Not to Know

If you prefer not to learn your genetic status, this is an option you should request. The study team should explicitly explain whether this is possible and document your preference during the informed consent process [3][6].

Choosing not to know is a deeply personal decision, and it is not always psychologically neutral. Research involving some families with inherited prion disease shows that high levels of anxiety can occur among both tested and untested individuals, and non-carriers may experience survivor’s guilt or ongoing family distress [7]. Participating in research without knowing your status can bring up complex emotions, so it is highly recommended to seek genetic counseling (guidance from a trained healthcare professional) to help navigate this choice [7][6].

A counselor can also explain penetrance (the likelihood that a person with the variant will develop the disease); while penetrance can vary widely among different PRNP variants, some FFI-associated variants are highly penetrant, meaning the disease is very likely to occur if the variant is present [8][9].

Safeguards and Risks of Accidental Disclosure

When participating in research without knowing your status, safeguards can reduce but cannot entirely eliminate the risk that your genetic status could be accidentally revealed or inferred.

Longitudinal research often involves repeated clinical visits and tests [5]. Differences in how study coordinators communicate with you, the specific procedures you undergo, or the side effects you experience from an intervention could provide clues about your underlying status [5].

Additionally, if your research results enter your standard electronic health record, your treating doctors or family members might unintentionally see them [5][10]. You should ask the research team exactly what privacy safeguards they use—such as keeping research records coded and entirely separate from clinical records, limiting who holds the key to the code, and whether a Certificate of Confidentiality or other legal privacy protection applies.

Future Use of Your Samples

When you join a study, biological samples (like blood or spinal fluid) might be stored in a biobank (a repository that stores biological samples for use in research) for future use. Future researchers might perform whole-genome sequencing or look at your PRNP gene, and policies on returning these future results vary by study [11][12].

While you can often ask to opt out of receiving optional genetic results from future research, you must check the specific limits outlined in your consent form [12]. Furthermore, once your samples or data have been de-identified, shared with outside researchers, or incorporated into aggregate analyses, it may no longer be possible to withdraw them [13][14].

Common questions in this guide

Can I participate in fatal familial insomnia research without learning my PRNP status?
Sometimes. Certain registries and prevention studies use a genotype-blinded or nondisclosure design, but each study has its own rules. Ask the research team about this preference before signing consent forms.
Will researchers test me for the PRNP variant if I do not want to know the result?
In a blinded study, researchers may test for the specific PRNP variant found in your family while withholding the result from you. Research testing is different from clinical testing, and a research finding generally needs confirmation with a clinically validated test before it guides medical decisions.
Can an FFI study accidentally reveal whether I carry the family variant?
Blinding safeguards can reduce but cannot completely eliminate accidental disclosure. Treatment assignment, study procedures, side effects, staff communication, or information placed in a medical record may provide clues, so ask how the study protects your privacy.
Should I speak with a genetic counselor before joining FFI research?
Yes, genetic counseling can help you consider the medical, emotional, and family implications of remaining unaware of your result. A counselor can also explain penetrance, which is the likelihood that a person with a particular PRNP variant will develop disease.
What happens to my blood or spinal fluid samples after an FFI study?
Samples may be stored in a biobank and used for future research, including genetic analysis, depending on the consent form. Ask whether you can decline future genetic results and what limits apply to withdrawing samples or data after they have been de-identified or shared.
What if I later want to learn my PRNP status or leave the study?
The study team should explain how to request disclosure or withdraw, but the options may be limited by the study design. Data or samples that have already been de-identified, shared, or included in combined analyses may no longer be retrievable.

Get notified when new evidence is published on Fatal familial insomnia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement.

    Forloni G, Roiter I, Artuso V, et al.

    Prion 2022; (16(1)):66-77 doi:10.1080/19336896.2022.2083435.

    PMID: 35737759
  2. 2

    Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases.

    Forloni G, Tettamanti M, Lucca U, et al.

    Prion 2015; (9(2)):75-9 doi:10.1080/19336896.2015.1027857.

    PMID: 25996399
  3. 3

    Genetic counseling for prion disease: Updates and best practices.

    Goldman JS, Vallabh SM

    Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(10)):1993-2003 doi:10.1016/j.gim.2022.06.003.

    PMID: 35819418
  4. 4

    A RaDiCAL gene hunt.

    Pupavac M, Zawati MH, Rosenblatt DS

    Journal of Taibah University Medical Sciences 2017; (12(3)):194-198 doi:10.1016/j.jtumed.2016.11.007.

    PMID: 31435239
  5. 5

    The natural history study of preclinical genetic Creutzfeldt-Jakob Disease (CJD): a prospective longitudinal study protocol.

    Bregman N, Shiner T, Kavé G, et al.

    BMC neurology 2023; (23(1)):151 doi:10.1186/s12883-023-03193-8.

    PMID: 37069531
  6. 6

    Genetic counseling and testing for Huntington's disease: A historical review.

    Nance MA

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2017; (174(1)):75-92 doi:10.1002/ajmg.b.32453.

    PMID: 27174011
  7. 7

    Genetic Testing in Prion Disease: Psychological Consequences of the Decisions to Know or Not to Know.

    Schwartz M, Brandel JP, Babonneau ML, et al.

    Frontiers in genetics 2019; (10()):895 doi:10.3389/fgene.2019.00895.

    PMID: 31616476
  8. 8

    Quantifying prion disease penetrance using large population control cohorts.

    Minikel EV, Vallabh SM, Lek M, et al.

    Science translational medicine 2016; (8(322)):322ra9 doi:10.1126/scitranslmed.aad5169.

    PMID: 26791950
  9. 9

    Mortality of Individuals With PRNP Variants Associated With Prion Disease in the United States, 1998-2024.

    Lian Y, Kotobelli K, Glisic K, et al.

    Neurology. Genetics 2026; (12(5)):e200423 doi:10.1212/NXG.0000000000200423.

    PMID: 42662715
  10. 10

    A Practice Framework for Genetic Testing in Asymptomatic Relatives of Patients With Creutzfeldt-Jakob Disease: Experience and Insights From Israel.

    Shir D, Bregman N, David AB, et al.

    European journal of neurology 2026; (33(6)):e70649 doi:10.1111/ene.70649.

    PMID: 42333775
  11. 11

    Development of Plain Language Supplemental Materials for the Biobank Informed Consent Process.

    Drake BF, Brown KM, Gehlert S, et al.

    Journal of cancer education : the official journal of the American Association for Cancer Education 2017; (32(4)):836-844 doi:10.1007/s13187-016-1029-y.

    PMID: 27037699
  12. 12

    An e-consent framework for tiered informed consent for human genomic research in the global south, implemented as a REDCap template.

    Tamuhla T, Tiffin N, Allie T

    BMC medical ethics 2022; (23(1)):119 doi:10.1186/s12910-022-00860-2.

    PMID: 36434585
  13. 13

    Using dataflow diagrams to support research informed consent data management communications: participant perspectives.

    McInnis BJ, Pindus R, Kareem DH, et al.

    Journal of the American Medical Informatics Association : JAMIA 2025; (32(4)):712-723 doi:10.1093/jamia/ocaf004.

    PMID: 39903169
  14. 14

    Patient consent to publication and data sharing in industry and NIH-funded clinical trials.

    Spence O, Onwuchekwa Uba R, Shin S, Doshi P

    Trials 2018; (19(1)):269 doi:10.1186/s13063-018-2651-2.

    PMID: 29724236

This page is for informational purposes only and does not constitute medical advice about FFI research or PRNP testing. Discuss study-specific privacy, consent, and genetic counseling questions with the research team and a qualified genetic counselor.